For Healthcare Professionals

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Must have metastatic colorectal or pancreatic cancer
  2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
  3. Ability to swallow pills or capsules
  4. Required to undergo mandatory pre and on-treatment biopsies
  5. Adequate marrow function
  6. Adequate other organ functions
  7. Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and pharmacodynamic (PD) sample collection, and required study follow-up

EXCLUSION CRITERIA

  1. Histology other than adenocarcinoma (neuroendocrine or acinar cell)
  2. Suspected, known, or central nervous system (CNS) metastases (Imaging required only if participants are symptomatic)
  3. Active, known or suspected autoimmune disease
  4. Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
  5. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
  6. Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (PD-1), programmed death-ligand 1 [PD(L)-1] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies
  7. History of allergy to study treatments or any of its components of the study arm that participant is enrolling Other protocol-defined inclusion/exclusion criteria apply
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall please email:Email iconEmail Study Center

Study’s details


Contition

Colorectal Cancer,Pancreatic Cancer

Age (in years)

18 - 200

Phase

Phase 1/Phase 2

Participants needed

332

Est. Completion Date

May 2023

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT03184870

Study number

CV202103

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.